Yarrow Bioscience, Inc. (YARW) stock
YARWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 11/30102% above fair value
$14.21+0.28 (+2.01%)
Close on Nov 17, 2026Market cap $37.94MP/E –Yield –
Yarrow Bioscience r&d expenses
Research and development expenses are spending on new products and technology.
Yarrow Bioscience's R&D Expenses for the twelve months ending Jun 30, 2025 was $30.94M, up 78.3% year over year. For fiscal 2025 it was $19.24M, down 37.8% from the year before. Over ten years it grew 20.7% a year on average. The highest annual figure on record is $64.47M in fiscal 2018.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.24M | -37.8% |
| FY2024 | Dec 31, 2024 | $30.95M | +89.8% |
| FY2023 | Dec 31, 2023 | $16.31M | -11.3% |
| FY2022 | Dec 31, 2022 | $18.39M | -5.9% |
| FY2021 | Dec 31, 2021 | $19.54M | -55.1% |
| FY2020 | Dec 31, 2020 | $43.53M | -15.0% |
| FY2019 | Dec 31, 2019 | $51.20M | -20.6% |
| FY2018 | Dec 31, 2018 | $64.47M | +122.3% |
| FY2017 | Dec 31, 2017 | $29.01M | +157.7% |
| FY2016 | Dec 31, 2016 | $11.26M | +285.3% |
| FY2015 | Dec 31, 2015 | $2.92M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $788.00K | -91.9% |
| Q1 FY2026 | Mar 31, 2026 | $817.00K | -92.0% |
| Q2 FY2025 | Jun 30, 2025 | $4.88M | -33.2% |
| Q1 FY2025 | Mar 31, 2025 | $6.12M | +65.2% |
| Q4 FY2024 | Dec 31, 2024 | $9.68M | +220.3% |
| Q3 FY2024 | Sep 30, 2024 | $10.25M | +208.9% |
| Q2 FY2024 | Jun 30, 2024 | $7.31M | +1.0% |
| Q1 FY2024 | Mar 31, 2024 | $3.71M | +35.6% |
| Q4 FY2023 | Dec 31, 2023 | $3.02M | -29.4% |
| Q3 FY2023 | Sep 30, 2023 | $3.32M | -40.2% |
| Q2 FY2023 | Jun 30, 2023 | $7.23M | +76.1% |
| Q1 FY2023 | Mar 31, 2023 | $2.73M | -38.6% |
| Q4 FY2022 | Dec 31, 2022 | $4.28M | -1.0% |
| Q3 FY2022 | Sep 30, 2022 | $5.55M | -6.3% |
| Q2 FY2022 | Jun 30, 2022 | $4.11M | -18.6% |
| Q1 FY2022 | Mar 31, 2022 | $4.45M | +4.6% |
| Q4 FY2021 | Dec 31, 2021 | $4.32M | -44.8% |
| Q3 FY2021 | Sep 30, 2021 | $5.92M | -10.7% |
| Q2 FY2021 | Jun 30, 2021 | $5.05M | -61.5% |
| Q1 FY2021 | Mar 31, 2021 | $4.26M | -73.3% |
| Q4 FY2020 | Dec 31, 2020 | $7.84M | -48.9% |
| Q3 FY2020 | Sep 30, 2020 | $6.62M | -46.8% |
| Q2 FY2020 | Jun 30, 2020 | $13.12M | +4.5% |
| Q1 FY2020 | Mar 31, 2020 | $15.95M | +47.1% |
| Q4 FY2019 | Dec 31, 2019 | $15.35M | -42.2% |
| Q3 FY2019 | Sep 30, 2019 | $12.45M | +16.7% |
| Q2 FY2019 | Jun 30, 2019 | $12.56M | -22.6% |
| Q1 FY2019 | Mar 31, 2019 | $10.85M | -1.6% |
| Q4 FY2018 | Dec 31, 2018 | $26.56M | +151.9% |
| Q3 FY2018 | Sep 30, 2018 | $10.67M | +33.2% |
| Q2 FY2018 | Jun 30, 2018 | $16.23M | +197.2% |
| Q1 FY2018 | Mar 31, 2018 | $11.02M | +120.8% |
| Q4 FY2017 | Dec 31, 2017 | $10.55M | – |
| Q3 FY2017 | Sep 30, 2017 | $8.01M | – |
| Q2 FY2017 | Jun 30, 2017 | $5.46M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.99M | – |
See a number that looks wrong?